New Research Points to Need for Standardized Peritoneal Mesothelioma Treatment, According to Surviving Mesothelioma

Jon Hopkins New Senior Vice President-Chief Development Officer of Legion Healthcare Partners

Over the past 23 years, Jon has held various positions at Varian Medical Systems including Director of Sales, Americas West & Latin America, Varian Proton Solutions and prior Director of Worldwide Sales, Varian Particle Therapy.

Sinan Batman Appointed CTO of TeraRecon

Batman brings rich industry experience to TeraRecon, including Chief Engineer at Carestream/Kodak Health Group, where he defined the vision for image-centric workflow information systems.

Teladoc Health Launches “myStrength Complete” As First Unified Mental Health Care Experience

Teladoc Health, Inc. (NYSE: TDOC) today announced the launch of myStrength Complete, an integrated mental health service providing personalized, targeted care to consumers in...

Scientists in Belgium and the US say there are currently too many different ways to deliver intraperitoneal chemotherapy, making it difficult to collect reliable treatment data.

Doctors at two Belgian universities and the Washington Cancer Institute in Washington, DC, are calling for more standardization of the peritoneal mesothelioma treatment that combines cytoreductive surgery and intraperitoneal chemotherapy (HIPEC). Surviving Mesothelioma has a more complete explanation in a new article. Click here to read it now.

The researchers say the problem is that mesothelioma doctors and others treating malignancies on the peritoneal surface do not use a consistent dose, duration or even drug for HIPEC.

“Although there is near universal standardization regarding the cytoreductive surgery, we are still lacking a much-needed standardization amongst the various intraperitoneal chemotherapy treatment modalities used today in clinical practice,” write the three authors, including Paul Sugarbaker, MD, of the Washington Cancer Institute.

According to the article in the International Journal of Hyperthermia, the combination of cytoreductive surgery and HIPEC is now the standard of care for peritoneal mesothelioma. But even among patients who have this treatment, peritoneal mesothelioma survival varies widely from just a few months to many years.

“Until there is more standardization in the way doctors treat peritoneal mesothelioma, it will be impossible to know how effective this treatment combination really is at extending mesothelioma survival,” says Alex Strauss, Managing Editor for Surviving Mesothelioma.

To read the details of the new CRS/HIPEC report, see Standardization Needed for Peritoneal Mesothelioma Treatment, now available on the Surviving Mesothelioma website.

Lemoine, L, et al, “Drugs, doses, and durations of intraperitoneal chemotherapy: standardizing HIPEC and EPIC for colorectal, appendiceal, gastric, ovarian peritoneal surface malignancies and peritoneal mesothelioma”, Volume 33, 2017, International Journal of Hyperthermia,



Subscribe to Medical Device News Magazine here.

Related Articles